The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats (Q50974329)

26 March 2018

title

The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats (English)

1 reference

26 March 2018

main subject

lurasidone

1 reference

ChEBI release 2020-05-28

M Horiguchi

1

1 reference

26 March 2018

H Y Meltzer

series ordinal

2

1 reference

26 March 2018

publication date

7 January 2012

1 reference

26 March 2018

number of pages

11

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

26 March 2018

volume

221

1 reference

26 March 2018

issue

2

1 reference

26 March 2018

page(s)

205-215

1 reference

26 March 2018

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

5HT antagonists attenuate MK801-impaired radial arm maze performance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

[3H]WAYâ 100635 for 5â HT1A receptor autoradiography in human brain: a comparison with [3H]8â OHâ DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Alterations in the cortical serotonergic system in schizophrenia: a postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Attention and higher cortical functions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Effects of ketamine in normal and schizophrenic volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The 5-HT 1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The 5-HT(1A) receptor active compounds (R)-8-OH-DPAT and (S)-UH-301 modulate auditory evoked EEG responses in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00213-011-2561-4

21 January 2018

12 December 2020

[3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

1 reference

12 December 2020

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

1 reference

12 December 2020

Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.

1 reference

12 December 2020

Declarative memory deficits and schizophrenia: problems and prospects

1 reference

12 December 2020

Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex

1 reference

12 December 2020

Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens

1 reference

12 December 2020

Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia

1 reference

12 December 2020

The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.

1 reference

12 December 2020

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

1 reference

12 December 2020

Glutamate and schizophrenia: beyond the dopamine hypothesis

1 reference

12 December 2020

10.1007/S00213-011-2561-4

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018